Date: 2018-09-11
Type of information: Nomination
Compound: member of the board of directors
Company: Amicus Therapeutics (USA - NJ)
Therapeutic area: Rare diseases - Genetic diseases - Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 11, 2018, Amicus Therapeutics announced the appointment of Lynn D. Bleil to its Board of Directors, effective immediately. Amicus also announced that current Director Michael G. Raab has been named Lead Independent Director. Mr. Raab will serve a three year term as Lead Director.
- Ms. Bleil has more than 25 years of experience in the healthcare sector, advising CEOs and Boards of leading healthcare companies on their most critical strategic, organizational and operational issues as a Senior Partner of McKinsey & Company. She has broad expertise in healthcare strategy, business development, go-to-market strategies, reimbursement and policy. Before retiring at the end of 2013, she led McKinsey & Company's West Coast Healthcare Practice, and was a core leader of McKinsey’s worldwide Healthcare Practice. Currently, Ms. Bleil serves on two public company healthcare Boards, including Sonova Holding and Stericycle. Previously, she served on the boards of DST Systems, Inc., and Auspex Pharmaceuticals until their sale to SS&C and Teva, respectively. She also serves on the Governing Board of Intermountain’s Park City Hospital. Ms. Bleil holds a bachelor's degree in chemical engineering from Princeton University, magna cum laude, and a master's degree in business administration from the Stanford Graduate School of Business, where she was an Arjay Miller Scholar.
Financial terms:
Latest news:
Is general: Yes
